关键词：囊性纤维化；粘液粘稠病；遗传性疾病
摘 要：Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, and secretion of abnormally viscous mucus. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. The incidence of cystic fibrosis varies between populations and is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but estimates range from 1 in 8,000 to 1 in 10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of the patient are dependent on the degree of bronchopulmonary involvement.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Zenpep/Ultresa/Ultrase/Ultrase MT

04.1.2 Colomycin/Colobreathe

04.1.3 Pulmozyme

04.1.4 Cayston

04.1.5 TOBI/TOBI Podhaler

04.1.6 Kalydeco

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Disease Overview

07.1 Understanding the Disease

07.2 Pathophysiology

07.3 Epidemiology

07.3.1 Global

07.3.2 North America

07.3.3 Europe

07.3.4 Africa

07.3.5 Latin America

07.3.6 Middle East

07.3.7 Asia and Oceania

07.4 Diagnosis

07.4.1 Carrier Testing

07.4.2 Antenatal Testing

07.4.3 Newborn Screening

07.4.4 Other Tests

07.5 Manifestations of Cystic Fibrosis

07.6 Economic Burden

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Five Forces Analysis

09. Segmentation of Global Cystic Fibrosis

Market by Molecule Type

09.1 Biologics

09.1.1 Enzymes

09.2 Small Molecules

09.2.1 CFTR Modulators

09.2.2 Antibiotics

10. Segmentation of Global Cystic Fibrosis

Market by Route of Administration

10.1 Oral

10.2 Parenteral

10.3 Topical

11. Segmentation of Global Cystic Fibrosis

Market by Dosage Form

11.1 Solid

11.2 Liquid

12. Geographical Segmentation of Global

Cystic Fibrosis Market

12.1 Cystic Fibrosis Market in Americas

12.1.1 Cystic Fibrosis Market in US

12.1.2 Cystic Fibrosis Market in Latin America

12.1.3 Cystic Fibrosis Market in Canada

12.2 Cystic Fibrosis Market in EMEA Region

12.2.1 Market Size and Forecast

12.3 Cystic Fibrosis Market in APAC Region

12.3.1 Market Size and Forecast

13. Key Leading Countries

13.1 US

13.2 UK

13.3 France

13.4 Canada

13.5 Italy

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.1.2 Mergers and Acquisitions

21.2 Global Cystic Fibrosis Market Share Analysis

2014

21.2.1 Hoffmann-La Roche

21.2.2 Novartis

21.2.3 Vertex Pharmaceuticals

21.2.4 Actavis

21.2.5 Gilead Sciences

21.3 Other and Future Prominent Vendors

22. Key Vendor Analysis

22.1 Actavis

22.1.1 Key Facts

22.1.2 Business Description

22.1.3 Business Segmentation

22.1.4 Business Segmentation by Revenue 2012 and 2013

22.1.5 Sales by Geography

22.1.6 Business Strategy

22.1.7 Key Information

22.1.8 SWOT Analysis

22.2 F. Hoffmann-La Roche Ltd.

22.2.1 Key Facts

22.2.2 Business Overview

22.2.3 Business Segmentation

22.2.4 Business Segmentation by Revenue 2012 and 2013

22.2.5 Sales by Geography

22.2.6 Business Strategy

22.2.7 Key Information

22.2.8 SWOT Analysis

22.3 Gilead Sciences

22.3.1 Key Facts

22.3.2 Business Overview

22.3.3 Geographical Segmentation by Revenue 2013

22.3.4 Recent Developments

22.3.5 SWOT Analysis

22.4 Novartis AG

22.4.1 Key Facts

22.4.2 Business Description

22.4.3 Business Segmentation3

22.4.4 Revenue by Business Segmentation

22.4.5 Revenue Comparison 2012 and 2013

22.4.6 Sales by Geography

22.4.7 Business Strategy

22.4.8 Key Developments

22.4.9 SWOT Analysis

22.5 Vertex Pharmaceuticals

22.5.1 Key Facts

22.5.2 Business Overview

22.5.3 Business Segmentation by Revenue 2013

22.5.4 Business Segmentation by Revenue 2012 and 2013

22.5.5 Geographical Segmentation by Revenue 2013

22.5.6 Business Strategy

22.5.7 Recent Developments

22.5.8 SWOT Analysis

23. Other Reports in this Series